Pembrolizumab in Combination with Axitinib as First-Line Treatment for Patients with Renal Cell Carcinoma (RCC): Evidence to Date

類似資料

• Pembrolizumab in Combination with Axitinib as First-Line Treatment for Patients with Renal Cell Carcinoma (RCC): Evidence to Date
  著者:: Chau, Vincent, 等
  出版事項: (2020)
• Real-World Therapy Management and Outcomes of First-Line Axitinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma in the United States
  著者:: Yousef Zakharia, 等
  出版事項: (2022-05-01)
• Combination of pembrolizumab and axitinib: a new gold standard in the first-line therapy for metastatic clear-cell renal-cell carcinoma?
  著者:: R. A. Gafanov, 等
  出版事項: (2020-09-01)
• Case Study: A Japanese patient with metastatic renal cell carcinoma who achieved long‐term treatment‐free survival with pembrolizumab and axitinib in the KEYNOTE‐426 phase III trial of pembrolizumab and axitinib versus sunitinib
  著者:: Koshiro Nishimoto, 等
  出版事項: (2022-05-01)
• Efficacy and safety of Tislelizumab combined with Axitinib as first-line treatment for intermediate- and high-risk metastatic clear-cell renal cell carcinoma
  著者:: Jie Cui, 等
  出版事項: (2025-05-01)